Directly integrated assays designed to satisfy CDSCO, US-FDA, and EMA regulatory frameworks from our certified laboratories.
Bridging the Western Indian pharma hub with international cell-based analytical precision.
The greater metropolitan region of Mumbai, encompassing pharmaceutical strongholds like Thane, Navi Mumbai, Tarapur, and the Pune-Mumbai bio-express corridor, functions as the commercial and intellectual capital of India's healthcare engine. Home to pharmaceutical giants, emerging clinical research organizations (CROs), and AYUSH-certified botanical manufacturers, Mumbai generates substantial demand for dependable, high-throughput in vitro testing methodologies. With global authorities like the US FDA enforcing the FDA Modernization Act 2.0—which officially removed the universal requirement for animal testing prior to human clinical trials—Mumbai manufacturers face immediate imperatives to integrate human-relevant, non-animal testing alternatives (NAMs) into their discovery pipelines.
Concurrently, the global in vitro testing sector is undergoing a massive transformation, shifting from basic 2D cell cultures to organ-on-a-chip (OOC) microfluidics, 3D spheroids, and AI-assisted predictive toxicology. Global contract manufacturers and testing suppliers serving Mumbai must provide not merely laboratory capacity, but comprehensive OECD 439/431 regulatory conformance, validated analytical chemistry (HPLC, HPTLC, LC-MS/MS), and automated phenotypic screening. MedGence bridges this gap by acting as a specialized contract research and manufacturing organization (CRO/CDMO), equipping Mumbai enterprises with evidence-based cellular assays that drastically lower lead optimization attrition rates.
Targeted in vitro screening models engineered for the operational realities of Western Indian enterprises.
Standardising active extracts from Sahyadri/Western Ghats botanicals using cellular anti-inflammatory (TNF-α, IL-6 inhibition) and antioxidant assays to substantiate export documentation for European and US nutraceutical buyers.
Enabling Mumbai’s generic formulation hubs to conduct high-throughput MTT cytotoxicity, neutral red uptake, and Ames bacterial reverse mutation tests to de-risk generic DMFs and new chemical entity (NCE) filings.
Meeting India’s 2014 regulatory ban on cosmetic animal testing via OECD 439 reconstructed human epidermis (RhE) skin irritation, Corrositex testing, and in vitro phototoxicity assays for export-focused beauty brands.
Transitioning from conventional flat-culture assays to dynamic micro-physiological human tissue surrogates.
High-throughput viability, LDH leakage, and live/dead fluorescent staining for initial lead triage.
Human primary hepatocyte and enterocyte spheroids for physiologically aligned ADMET screening.
Microfluidic tissue chips recreating vascular shear stresses, gut barriers, and renal clearance dynamics.
Automated machine learning models predicting clinical endpoints directly from high-content imaging data.
Direct answers covering protocol validation, sample transfer, and regulatory acceptability.
Explore our full line of extraction, screening, animal evaluation, and clinical manufacturing services.
